TMO vs WAT
Thermo Fisher Scientific and Waters Corporation, both Healthcare
Thermo Fisher Scientific is the larger company at $256B against $46B. On trailing earnings TMO is the cheaper of the two at a P/E of 37.3 against 116.9, a gap that is only a bargain if the two are growing at similar rates. Over the past year WAT returned +37% against +28% for TMO. The RyuScore puts WAT ahead, 49 against 45 out of 100.
| Figure | TMO | WAT |
|---|---|---|
| Last close | $693 | $469 |
| Market cap | $256B | $46B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 37.3 | 116.9 |
| Dividend yield | 0.3% | n/a |
| 1-year return | +28% | +37% |
| 5-year return | +22% | +37% |
| RyuScoresector-relative, 1–10 | 45/100 | 49/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Thermo Fisher Scientific
Revenue of $12B in Q2 2026, net income $1.7B. Its largest reported line is Life Sciences Solutions, 38% of the disclosed total.
Waters Corporation
Revenue of $1.6B in Q2 2026, net income null. Its largest reported line is Consumables, 47% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.